Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

HDAC6-IN-13

😃Good
Catalog No. T61474

HDAC6-IN-13 (Compound 35m) is a potent and highly selective orally active inhibitor of HDAC6, with an IC50 of 0.019 μM. It also inhibits HDAC1, HDAC2, and HDAC3, with IC50 values of 1.53 μM, 2.06 μM, and 1.03 μM, respectively. HDAC6-IN-13 exhibits substantial blood-brain barrier permeability and anti-inflammatory properties [1].

HDAC6-IN-13

HDAC6-IN-13

😃Good
Catalog No. T61474
HDAC6-IN-13 (Compound 35m) is a potent and highly selective orally active inhibitor of HDAC6, with an IC50 of 0.019 μM. It also inhibits HDAC1, HDAC2, and HDAC3, with IC50 values of 1.53 μM, 2.06 μM, and 1.03 μM, respectively. HDAC6-IN-13 exhibits substantial blood-brain barrier permeability and anti-inflammatory properties [1].
Pack SizePriceAvailabilityQuantity
25 mg$1,52010-14 weeks
50 mg$1,98010-14 weeks
100 mg$2,50010-14 weeks
Bulk & Custom
Add to Cart
Questions
View More
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
HDAC6-IN-13 (Compound 35m) is a potent and highly selective orally active inhibitor of HDAC6, with an IC50 of 0.019 μM. It also inhibits HDAC1, HDAC2, and HDAC3, with IC50 values of 1.53 μM, 2.06 μM, and 1.03 μM, respectively. HDAC6-IN-13 exhibits substantial blood-brain barrier permeability and anti-inflammatory properties [1].
In vitro
HDAC6-IN-13 (Compound 35m), at concentrations ranging from 0.1 to 1 μM over 24 hours, demonstrates high selectivity for HDAC6 over class I HDAC enzymes. This compound is characterized by its slow-on and slow-off tight-binding inhibition of HDAC6, contrasting with its rapid binding affinity for HDAC1, 2, and 3. Furthermore, HDAC6-IN-13 exhibits anti-inflammatory effects in vitro at higher concentrations of 5 to 20 μM after an 8-hour exposure. Western Blot Analysis on the MV4 11 and J774A.1 cell lines, using 0.1, 0.2, 0.5, and 1 μM concentrations for 24 hours, revealed a concentration-dependent increase in acetylated tubulin (Ac-Tubulin), with no significant changes in acetylated histone H3 (AcHH3) and H4 (AcHH4) at the 1 μM level. Another analysis on J774A.1 cells, at concentrations of 5, 10, and 20 μM for 8 hours, demonstrated dose-dependent inhibition of pro-caspase 1 cleavage to p20 and prevented the interaction between HDAC6 and dynein, highlighting its potential for therapeutic applications in inflammation and cancer.
In vivo
HDAC6-IN-13 (Compound 35m), administered at 20 mg/kg both orally (p.o.) and intraperitoneally (i.p.), significantly reduces LPS-induced inflammation in mice, demonstrating potent anti-inflammatory effects. When administered orally at the same dosage, it exhibits high bioavailability (93.4%) and substantial blood-brain barrier (BBB) permeability. Tested in male C57BL/6 WT mice using an LPS-induced endotoxic shock model and male CD-1 mice for pharmacokinetic studies, HDAC6-IN-13 significantly decreased serum IL-1β levels. Pharmacokinetic analysis revealed a maximum plasma concentration (Cmax) of 4604 ± 551 ng/mL (i.v., 5 mg/kg) and 5570 ± 551 ng/mL (p.o., 20 mg/kg), half-life (t1/2) of 7.95 ± 0.370 h (i.v.) and 6.80 ± 0.145 h (p.o.), and area under the curve (AUC) of 2755 ± 395 ng·h/mL (i.v.) and 10292 ± 1385 ng·h/mL (p.o.). Blood samples analyzed via LC-MS/MS confirm the compound's effective delivery and promising pharmacodynamic profile for combatting inflammation.
Chemical Properties
Molecular Weight370.45
FormulaC23H22N4O
Storage & Solubility Information
StorageShipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy HDAC6-IN-13 | purchase HDAC6-IN-13 | HDAC6-IN-13 cost | order HDAC6-IN-13 | HDAC6-IN-13 in vivo | HDAC6-IN-13 in vitro | HDAC6-IN-13 formula | HDAC6-IN-13 molecular weight